ITRM Stock Overview
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Iterum Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.54 |
52 Week High | US$2.50 |
52 Week Low | US$0.62 |
Beta | 2.35 |
1 Month Change | 16.67% |
3 Month Change | -21.83% |
1 Year Change | 54.74% |
3 Year Change | -92.97% |
5 Year Change | -98.77% |
Change since IPO | -99.20% |
Recent News & Updates
Recent updates
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Aug 19Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03
Aug 12Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate
Jul 11Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
May 06Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Jan 12Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?
Sep 25Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy
Jul 05It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year
Jun 11Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?
May 20Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?
Feb 04This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)
Feb 04Iterum Therapeutics shares slide 13% on raising $10M
Feb 03Iterum Therapeutics rises 39% on RA Capital stake disclosure
Dec 03Iterum Therapeutics files US application for sulopenem in urinary tract infections
Nov 30Iterum Therapeutics EPS beats by $0.45
Nov 16Shareholder Returns
ITRM | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -2.5% | 1.2% | 0.4% |
1Y | 54.7% | 25.8% | 28.8% |
Return vs Industry: ITRM exceeded the US Pharmaceuticals industry which returned 25.8% over the past year.
Return vs Market: ITRM exceeded the US Market which returned 28.8% over the past year.
Price Volatility
ITRM volatility | |
---|---|
ITRM Average Weekly Movement | 12.0% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ITRM's share price has been volatile over the past 3 months.
Volatility Over Time: ITRM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 14 | Corey Fishman | https://www.iterumtx.com |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics plc Fundamentals Summary
ITRM fundamental statistics | |
---|---|
Market cap | US$21.36m |
Earnings (TTM) | -US$31.10m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs ITRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ITRM income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$31.10m |
Earnings | -US$31.10m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.31 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 570.9% |
How did ITRM perform over the long term?
See historical performance and comparison